Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00049660]
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00049660]
Bio2RDF identifier
NCT00049660
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00049660
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... ly treated with chemotherapy.
brief title [clinicaltrials_vocabulary:brief-title]
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: Phase II St ...... his study within 18.5 months.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2002-11-12T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
stage IV breast cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-07-17T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00049660
official title [clinicaltrials_vocabulary:official-title]
A Randomized Phase II-III Tria ...... eated Metastatic Breast Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
EORTC-10001-160010
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-12-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
EORTC-10001
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2002-09-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-07-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
low accrual
identifier
clinicaltrials:NCT00049660
title
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
@en
type
label
Capecitabine Compared With Vin ...... r [clinicaltrials:NCT00049660]
@en